Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Smoldering Multiple Myeloma 1Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 13Lenalidomide 11daratumumab 5carfilzomib 5Bortezomib 5Calcium Dobesilate 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Cyclophosphamide 3ixazomib 2isatuximab 2fludarabine phosphate 2fludarabine 2belantamab mafodotin 2Etoposide 2venetoclax 1thymoglobulin 1selinexor 1pomalidomide 1poly ICLC 1citarinostat 1Transplantation 1Thalidomide 1Sirolimus 1Rituximab 1Positron Emission Tomography Computed Tomography 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Plasma Cell × citarinostat × Clear all
NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Massachusetts General Hospital

Phase 1 Active not recruiting
19 enrolled
Plasma cell

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡